Novartis terminates Femara deal with Chugai in Japan

7 January 2016

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) and the local subsidiary of Swiss pharma giant Novartis (NOVN: VX) have agreed to terminate the agreement regarding co-marketing of the aromatase inhibitor Femara (letrozole)tablets, a treatment for breast cancer after menopause in Japan, as of January 31, 2016.

Novartis Pharma KK will be solely responsible for the distribution and commercialization of Femarain Japan from February 1, 2016. The companies first started co-marketing of the drug in 2006. No reason for the latest decision was provided.

Chugai, which is majority-owned by Swiss major Roche (ROG: SIX), and Novartis Pharma will cooperate to accomplish a smooth transition. During the transition period, both companies will maintain the same level of product supply and adequate commercial activities to satisfy any medical needs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK